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Material and Methods: This study reviewed cancer registry 
data of our hospital from 2004 to 2012 with following 
inclusion criteria: ESC were found at least 90 days after HNC 
in the same patient, and both were diagnosed with pathology 
of invasive cancer. Patients would be excluded with following 
criteria: ESC was an extension of HNC or vice versa, and no 
available information of treatment could be retrieved. 
Treatment was composed by combinations of radiotherapy, 
chemotherapy, and surgery depending on disease status and 
performance status of the patient. The primary end point 
was overall survival (OS), and the second endpoint was 
progression-free survival (PFS). 
 
Results: 77 patients were eligible. The median time from 
HNC to ESC was 32 months (4 – 147 months). Fifty-three 
patients (60%) were stage III/IV and 15 patients received best 
supportive care only after diagnosis of ESC. After excluding 
the BSC group, the 2-year OS were 34.9%. Fifteen patients 
were alive and one of them still had ESC. Thirty-five, 10, and 
2 patients died from ESC, treatment related complications, 
and other disease, respectively. Univariate analysis revealed 
that ECOG > 1, tube feeding, anemia, and no esophagectomy 
correlated with poor OS (p < 0.05). Multivariate analysis 
showed that lower hemoglobin level, habit of smoking, ECOG 
score = 2, and no esophagectomy were independent poor 
prognostic factors (p < 0.05). The 2-year PFS rate for all 
patients was 30.7%. In the univariate analysis, ECOG > 1, tube 
feeding, body weight loss > 5%, anemia, no esophagectomy, 
and ESCstage III/IV were significantly correlated with poor 
PFS (p < 0.05). In the multivariate analysis, anemia and no 
esophagectomy were independently correlated with tumor 
recurrence (p < 0.05). Treatment outcome of patients who 
received esophagectomy were similar to ESC patients without 
prior history of HNC. The 2-year OS and PFS were 63.9% and 
50.6%, respectively. Both were significantly higher than 
patients who did not receive esophagectomy (11.8% and 9.9%, 
p < 0.01). 
 
Conclusion: the treatment result of metachronous ESC after 
HNC varied with disease and patient status. If esophagectomy 
was possible, the treatment outcome was not inferior to 
esophageal cancer without prior head and neck cancer 
history. But the treatment outcome was poor in patients with 
unresectable disease or poor performance status. A screening 
program for metachronous ESC should be considered for high 
risk patients to detect resectable ESC and improve treatment 
outcome. 
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Purpose or Objective: Evaluate the salvage radiotherapy 
outcome in patients with supraclavicular lymph node 
metastases (SCLN) after esophagectomy. 
 
Material and Methods: A total of 117 patients with 
esophageal squamous cell carcinoma after initial 
esophagectomy (R0 resection) were retrospectively analyzed 
and they were diagnosed supraclavicular lymph node 
metastases during follow-up time. All patients were divided 
into salvage radiotherapy group (SR, n=89) and no salvage 
radiotherapy group (NSR, n=27). 
 
Results: The 1,3,5-year overall survival rates were 
81.6%、31.4%、8.6%, respectively. In all patients the 1,3-year 
survival time after SCLN metastasis (ASMS) rates were 
40.2%、14.5%, and the median ASMS time was 10 months. 
The 1, 3-year ASMS rates were 48.1%、18.9% in SR group and 
12.0%、0% in NSR group,respectively (P<0.001). In SR group, 
the 1, 3-year ASMS rates in the patients with combined 
radiochemotherapy and single radiotherapy were 62.6%, 
33.4% and 41.9%, 16.5% (P<0.001). In the subgroup analysis, 
in combining visceral metastases group (CVM), the 1,3-year 
ASMS rates were 35.5% , 0%, and 42.3%, 21.5% in no 
combining visceral metastases group (NCVM) (P = 0.004). The 
3-year ASMS rate with the patients in no combining 
mediastinal failure group (NCMF) (22.2%) was higher than 
those in combining mediastinal failure group (CMF) (7.0%) 
(p=0.041). According to the salvage radiation dose, the 1,3-
year ASMS rates were 56.5%, 23.4% in ≥60Gy group and 29.2%, 
7.5% in <60Gy group (p<0.001). Multivariate factor analysis 
revealed that combining visceral metastases, combining 
mediastinal failure, salvage radiotherapy, salvage radiation 
dose and salvage treatment model may be considered 
favourable prognostic factors. 
 
Conclusion: Salvage radiotherapy may improve survival of 
patients with supraclavicular lymph node metastases after 
esophagectomy. Combined radiochemotherapy and no 
combining visceral metastases and a salvage radiation dose 
≥60 Gy were associated with a better prognosis for those 
patients. 
 
PO-0701  
Dose-response relationship for locoregional control in 
esophageal cancer treated with curative CRT 
H.J. Kim
1Yonsei University, Radiation Oncology, Seoul, Korea 
Republic of 
1, Y.G. Suh1, W.S. Koom1, Y.B. Kim1, C.G. Lee1 
 
Purpose or Objective: To evaluate the correlation between 
radiation dose and locoregional control (LRC) for patients 
with stage II-III esophageal cancer treated with definitive 
concurrent chemo-radiotherapy (CCRT). 
 
Material and Methods: The medical records of 236 patients 
with clinical stage II and III esophageal cancer treated with 
definitive CCRT at the Yonsei Cancer Center between Feb 
1994 and May 2013 were retrospectively reviewed. Among 
these patients, 120 received a radiation dose of < 60 Gy 
(standard-dose group), while 116 received a radiation dose of 
≥ 60 Gy (high-dose group). The median dose of radiation in 
the standard and high dose groups was 50.4 Gy (range, 45.0-
59.4 Gy) and 63 Gy (range, 60.0-66.6 Gy). Concurrent 5-
FU/cisplatin (FP) chemotherapy (CHT) was performed in 82.2 
% of patients. 
 
Results: The patient characteristics had no differences in 
age, sex, pathology, grade, tumor length, and clinical stage 
between the two groups. Patients with high Karnofsky 
performance status scale and lower thoracic esophageal 
tumor were included more in standard dose group (p = 0.017 
and 0.038). Maintenance CHT was performed more in 
standard dose group (45% versus 30.2%, p = 0.037) and FP 
CHT was more frequently used in high dose group (76.7% vs. 
87.9%, p = 0.019). The median follow-up time for all patients 
was 19.2 months (range, 2.2-164.7). Of all patients, 2-yr and 
5-yr LRC rate were 60.0% and 48.4%. The median progression-
free survival (PFS) and overall survival (OS) were 13.2 months 
and 26.2 months, respectively. Patients in the high-dose 
group had a significantly better LRC (2-yr LRC rate, 50.3% vs. 
69.1%, p = 0.002), PFS (median, 11.7 vs. 16.7 months, p = 
0.029) and OS (median, 22.3 vs. 35.1 months, p = 0.043). The 
complete clinical response (CR) rate was significantly higher 
in the high-dose group (44.2% vs. 62.1%, p = 0.007). The 
treatment-related toxicities did not show a significant 
difference between the both groups (p = 0.936), although it 
was difficult to assess due to a retrospective fashion. On 
multivariate analysis, sex (female), radiation dose (≥ 60 Gy) 
and use of maintenance CHT were independent predictors for 
improved LRC, and sex (female), clinical stage (stage II vs. 
III), radiation dose (≥ 60 Gy) and use of maintenance CHT 
were significant predictive factors for OS. 
 
Conclusion: A higher radiation dose of > 60 Gy is associated 
with increased LRC, PFS and OS for patients with stage II-III 
esophageal cancer treated with definitive CCRT. 
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Purpose or Objective: The prognosis of oesophageal cancer 
(OC) is poor, with overall 5-year survival approximately 15%. 
The presence of lymph node metastases (LNMs) is a major 
prognostic indicator and the ability to identify LNMs is 
important. Texture analysis of medical images enables 
additional information to be extracted from routine staging 
investigations and quantifies intra-tumoural characteristics 
via non-invasive methods. The aim of the study is to obtain 
preliminary data investigating the association of texture 
variables and LNMs. 
 
Material and Methods: A prospectively maintained database 
including clinical, radiological and pathological details of 
consecutive OC patients with biopsy proven adenocarcinoma 
in South East Wales from October 2010 to August 2013 was 
retrospectively analysed. All patients underwent PET/CT 
staging. Consecutive patients were grouped into those with 
and without LNMs on endoscopic ultrasound (EUS), considered 
the superior staging investigation for loco-regional 
assessment. Texture analysis of the primary tumour was 
carried out on the PET images using PET-STAT, software 
developed and written in the Matlab-based open source 
software CERR. The tumour was outlined with ATLAAS, a 
learning algorithm for optimised automatic segmentation 
developed at Cardiff University. Seventeen variables 
including SUVmax, metabolic tumour volume (MTV), total 
lesion glycolysis (TLG) and intensity variability (IV) were 
calculated. Table 1 details all variables calculated. Patients 
with primary tumour volume less than 5 ml and distant 
metastatic disease were excluded. Independent T-tests were 
used to identify promising texture variables for future study. 
A p-value <0.05 was considered significant. Primary outcome 
was LNMs on EUS. 
 
Results: Eighty-one patients underwent staging with PET/CT 
and EUS [male 67, median age 66 (range 42-82)]. Forty 
patients were staged as N0 on EUS, with 41 having evidence 
of regional lymph node metastases. Independent T-tests 
demonstrated significant differences between patients with 
and without LNMs for MTV [mean 38.45 v 21.71; t(56.03)=-
2.449, p=0.017], TLG [mean 328.72 v 208.66; t(74.721)=-
2.023, p=0.047], Coarseness [mean 0.010 v 0.013; 
t(79)=3.107, p=0.003], Entropy [mean 6.15 v 5.91; t(79)=-
2.075, p=0.041] and IV [mean 21.09 v 13.45; t(64.366)=-
2.458, p=0.017]. 
 
Conclusion: Preliminary results have shown a number of 
texture variables that have the potential to predict LNMs. 
On-going work at our institution is investigating the added 
benefit of texture analysis when developing robust clinical 
predictive models. 
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Purpose or Objective: Perioperative chemotherapy (pCT) 
and neoadjuvant chemoradiotherapy (nCRT) are well-
established therapies to improve survival for resectable non-
metastatic esophageal carcinoma. However, the optimal type 
of treatment for esophageal adenocarcinoma is currently 
under debate. Until now, limited evidence is available to 
determine whether pCT or nCRT is most beneficial with 
regard to toxicity, pathologic outcome and survival. 
Therefore, the aim of this study was to compare toxicity, 
pathologic outcome and survival after pCT versus nCRT and 
surgery in patients with esophageal adenocarcinoma. 
 
Material and Methods: Consecutive patients who underwent 
pCT or nCRT followed by esophagectomy for cancer between 
October 2006 and September 2015 in a single institution were 
analyzed. The pCT regimen consisted of intravenous 
administration of epirubicin, cisplatin and capecitabin, 
whereas nCRT consisted of paclitaxel and carboplatin with 
concurrent radiotherapy. Toxicity of grade 3 or higher was 
scored according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events. Data on surgical 
procedures, complications and follow-up were collected from 
a prospectively maintained database. Full propensity score-
matching was applied to generate matched sets of cases 
based on pretreatment covariates in order to create 
comparable groups. Univariable analysis was performed to 
determine differences between the two groups. Disease-free 
survival (DFS) and overall survival (OS) were assessed using 
the Kaplan-Meier method and log-rank test. 
 
Results: A total of 189 eligible patients were identified of 
whom 19 were discarded after propensity matching; 86 
underwent pCT and 84 received nCRT. During preoperative 
therapy, thromboembolic events occurred more frequently in 
the pCT group (18% vs. 0%, p<0.001), while leukopenia 
occurred more frequently in the nCRT group (25 vs. 11%, 
p=0.013). Complete resection with no tumor within 1 mm of 
the resection margins (R0) was achieved in 90% of patients in 
the pCT group, as opposed to 96% in the nCRT group 
(p=0.103). Pathologic tumor regression was more frequently 
observed in patients who underwent nCRT compared to pCT 
(p<0.001). There was no significant difference between the 
groups with regard to risk of surgical complications, length of 
hospital stay or in-hospital mortality. Both treatments 
resulted in comparable 3-year DFS (49% vs. 53% for pCT and 
nCRT, respectively, log-rank p=0.774) and OS rates (48% vs. 
51%, log-rank p=0.842) (Figure 1). 
 
 
Conclusion: Perioperative chemotherapy (MAGIC) and 
neoadjuvant chemoradiotherapy (CROSS) were associated 
with comparable toxicity and postoperative morbidity. 
Although neoadjuvant chemoradiotherapy was associated 
with improved tumor regression compared to perioperative 
chemotherapy, this finding did not translate into improved R0 
resection or 3-year survival rates. 
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